CARGO Therapeutics, Inc. Common Stock (CRGX) - Net Assets
Based on the latest financial reports, CARGO Therapeutics, Inc. Common Stock (CRGX) has net assets worth $237.70 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($258.61 Million) and total liabilities ($20.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are CARGO Therapeutics, Inc. Common Stock's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $237.70 Million |
| % of Total Assets | 91.92% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CARGO Therapeutics, Inc. Common Stock - Net Assets Trend (2021–2024)
This chart illustrates how CARGO Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore CARGO Therapeutics, Inc. Common Stock (CRGX) total assets for the complete picture of this company's asset base.
Annual Net Assets for CARGO Therapeutics, Inc. Common Stock (2021–2024)
The table below shows the annual net assets of CARGO Therapeutics, Inc. Common Stock from 2021 to 2024. For live valuation and market cap data, see CARGO Therapeutics, Inc. Common Stock (CRGX) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $360.23 Million | -11.14% |
| 2023-12-31 | $405.39 Million | +1250.49% |
| 2022-12-31 | $-35.24 Million | -20034.86% |
| 2021-12-31 | $-175.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to CARGO Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 30660000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $46.00K | 0.01% |
| Other Comprehensive Income | $291.00K | 0.08% |
| Other Components | $672.54 Million | 186.70% |
| Total Equity | $360.23 Million | 100.00% |
CARGO Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of CARGO Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Re Max Holding
NYSE:RMAX
|
$216.21 Million |
|
Orchestra BioMed Holdings Inc.
NASDAQ:OBIO
|
$216.26 Million |
|
UJU Electronics Co. Ltd
KQ:065680
|
$216.27 Million |
|
DAEA TI Co. Ltd
KQ:045390
|
$216.31 Million |
|
Creditwest Faktoring AS
IS:CRDFA
|
$216.09 Million |
|
New Era Energy & Digital, Inc.
NASDAQ:NUAI
|
$215.93 Million |
|
Virginia National Bankshares Corp
NASDAQ:VABK
|
$215.91 Million |
|
AurosTechnology Inc.
KQ:322310
|
$215.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CARGO Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 405,386,000 to 360,229,000, a change of -45,157,000 (-11.1%).
- Net loss of 167,502,000 reduced equity.
- New share issuances of 102,888,000 increased equity.
- Other comprehensive income increased equity by 453,327,000.
- Other factors decreased equity by 433,870,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-167.50 Million | -46.5% |
| Share Issuances | $102.89 Million | +28.56% |
| Other Comprehensive Income | $453.33 Million | +125.84% |
| Other Changes | $-433.87 Million | -120.44% |
| Total Change | $- | -11.14% |
Book Value vs Market Value Analysis
This analysis compares CARGO Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.56x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-0.01 | $4.47 | x |
| 2022-12-31 | $-1.83 | $4.47 | x |
| 2023-12-31 | $9.84 | $4.47 | x |
| 2024-12-31 | $8.01 | $4.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CARGO Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -46.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.15x
- Recent ROE (-46.50%) is below the historical average (-17.68%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.83 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-37.43 Million |
| 2023 | -24.21% | 0.00% | 0.00x | 1.12x | $-138.69 Million |
| 2024 | -46.50% | 0.00% | 0.00x | 1.15x | $-203.52 Million |
Industry Comparison
This section compares CARGO Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CARGO Therapeutics, Inc. Common Stock (CRGX) | $237.70 Million | 0.00% | 0.09x | $216.19 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About CARGO Therapeutics, Inc. Common Stock
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, focused on designing, engineering, and developing potentially curative cell therapies for cancer patients in the United States. The company develops CRG-023, a tri-specific CAR T product candidate which is in phase 1 that targets tumor cells with three B-cell malignancies; and allogeneic platform, a universal vector solution design… Read more